Incorporating Newer Agents in the Treatment of Acute Myeloid Leukemia

Acute myeloid leukemia (AML) represents a malignant clonal expansion of myeloid progenitor cells in the peripheral blood and bone marrow. Overall, the prognosis in AML is suboptimal, with less than 30% of AML patients achieving a long-term remission. When factoring age, as older patients are not often offered intensive therapy, survival in this group is even more morbid, and is often measured only in months. [1] Recently, through advancements in cytogenetic and next generation techniques, there has been a substantial improvement in the understanding of the wide genomic landscape in AML.
Source: Leukemia Research - Category: Hematology Authors: Source Type: research